Biomind Labs（BMND）株式概要バイオテクノロジー研究開発企業であるバイオマインド・ラボ社は、さまざまな精神・神経疾患のための新規医薬品とナノテク送達システムの開発に注力している。 詳細BMND ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( $0 )キャッシュランウェイが1年未満である 意味のある時価総額がありません ( CA$13M )+1 さらなるリスクすべてのリスクチェックを見るBMND Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.10該当なし内在価値ディスカウントEst. Revenue$PastFuture-37m12016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesBiomind Labs Inc. 競合他社AvicannaSymbol: TSX:AVCNMarket cap: CA$13.8mCrescita TherapeuticsSymbol: TSX:CTXMarket cap: CA$14.7mNeurothera LabsSymbol: TSXV:NTLXMarket cap: CA$15.3mLIR Life SciencesSymbol: CNSX:SKNYMarket cap: CA$11.1m価格と性能株価の高値、安値、推移の概要Biomind Labs過去の株価現在の株価US$0.1052週高値US$0.3252週安値US$0.01ベータ7.31ヶ月の変化-16.00%3ヶ月変化600.00%1年変化n/a3年間の変化-75.00%5年間の変化n/aIPOからの変化-93.14%最新ニュースNew Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$134k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$134k free cash flow). Shares are highly illiquid. Negative equity (-US$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.31m).お知らせ • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.お知らせ • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.Board Change • Dec 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Scott Ackerman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.Board Change • Mar 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.最新情報をもっと見るRecent updatesNew Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$134k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$134k free cash flow). Shares are highly illiquid. Negative equity (-US$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.31m).お知らせ • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.お知らせ • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.Board Change • Dec 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Scott Ackerman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.Board Change • Mar 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jan 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jan 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.New Risk • Nov 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (74% average weekly change). Negative equity (-US$1.1m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (CA$33.4m market cap, or US$23.8m).お知らせ • Jul 19Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical TrialBiomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays.Board Change • Jun 04No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Dec 07No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Shares are highly illiquid. Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (CA$10.1m market cap, or US$7.48m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end).Board Change • Nov 24No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Nov 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$10.3m (US$7.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Shares are highly illiquid. Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (CA$10.3m market cap, or US$7.48m).Board Change • Nov 07No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Oct 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Sep 15Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical ApplicationsBiomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges.Board Change • Aug 25No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Jun 23No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 10No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Dec 29Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s DiseaseBiomind Labs Inc. announced that it has successfully completed the development of a novel sublingual formulation to be used in the Phase II trial for its 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”)-based BMND08 candidate for the potential treatment of depression and anxiety in Alzheimer’s disease.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 15Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant DepressionBiomind Labs Inc. announced that the U.S. Food and Drug Administration (“FDA”) has given the Company Investigational New Drug (“IND”) clearance related to the Company’s New Chemical Entity (“NCE”) Triptax™.お知らせ • Nov 05Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant DepressionBiomind Labs Inc. announced positive initial results from part I of its Phase II trial on its BMND01 candidate, a novel liquid inhaled formulation of N,N-Dimethyltryptamine (DMT) for Treatment-Resistant Depression (TRD). The trial, led by Professor Dráulio Araújo, Ph.D., has involved a dose exploration schedule ranging from 5 to 100 mg. No volunteer presented serious adverse events or clinical risk to the 11 different doses tested. The experimental design of this open-label ascending dose trial involved developing and implementing a proprietary clinical-experimental protocol based on the fundamentals of interventional psychiatry. This multidisciplinary approach combines a psychiatric procedure for dosing DMT associated with psychological support under strict clinical standards.お知らせ • Oct 12Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant DepressionBiomind Labs Inc. announced a Pre-Investigational New Drug (“Pre-IND”) meeting granted by the U.S. Food and Drug Administration (the “FDA”) for the Company’s new chemical entity (“NCE”) Triptax™. The Company has submitted a briefing package to the Division of Psychiatry, Center for Drug Evaluation and Research at the FDA, and awaits further feedback on the NCE Triptax™. The Pre-IND meeting is a critical step in the U.S. regulatory approval process that provides an opportunity for the Company and the FDA to discuss the NCE development plan and to obtain the FDA’s guidance for new clinical trials the Company may conduct on the NCE Triptax™.お知らせ • Sep 28Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery SystemBiomind Labs Inc. announced the receipt of a Controlled Substances License and the commencement of an eight-month project to produce and evaluate novel rapidly-dissolving and sustained-release hydrogel-forming microneedle arrays designed for the transdermal delivery of Biomind’s key psychedelic compounds: N, N-dimethyltryptamine (“DMT”), 5-methoxyN,N-dimethyltryptamine (“5-MeO-DMT”) and mescaline. The use of polymeric microneedle array patches (“MAPs”) is an attractive way of delivering drugs through the skin. Upon MAP application, microneedles painlessly penetrate the outer layer of the skin, creating temporary microchannels in this highly effective barrier to diffusion, through which enhanced transdermal drug delivery can be achieved. Given the presence of a dense network of blood vessels in the deeper layers of the skin, drugs can be absorbed into the plasmatic circulation and distributed to the entire body, producing a systemic effect. Additional advantages of this technology, such as the avoidance of first-pass metabolism and drug delivery in a rate-controlled or long-acting manner, can serve to reduce the incidence of side-effects and dosing frequency, which in turn may lead to increased treatment adherence.お知らせ • Sep 22Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant DepressionBiomind Labs Inc. announced the completion of dose administration of 30 healthy subjects in the Company’s Phase II trial of its novel drug candidate BMND01 for Treatment-Resistant Depression. 10% to 30% of people with depression exhibit treatment-resistant symptoms coupled with difficulties in social and occupational function, decline of physical health, poor quality of life, suicide ideation and attempts, self-injurious behavior, high relapse rate and increased health care utilization. The objectives of the trial are to establish the safety and tolerability of DMT. In addition to evaluating side effects, thistrial will also allow Biomind to explore the origin of the observed side effects, given that different associated physiological, behavioral, and cognitive markers will be collected before, during, and after the trial.Board Change • Jul 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 08Biomind Labs Inc., Annual General Meeting, Jun 28, 2022Biomind Labs Inc., Annual General Meeting, Jun 28, 2022, at 10:00 US Eastern Standard Time. Agenda: To receive the audited financial statements of the Corporation for the financial year ended December 31, 2021, together with the report of the auditor thereon; to appoint MNP LLP, Chartered Professional Accountants, as auditor of the Corporation for the ensuing year and to authorize the directors of the Corporation to fix the remuneration of the auditor; to elect the directors of the Corporation for the ensuing year; and to transact such other business as may properly be brought before the Meeting or any adjournment or adjournments thereof.お知らせ • May 27Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s DiseaseBiomind Labs Inc. announced that a third Phase II clinical trial for its BMND08 candidate based on 5-Methoxy-N,N-dimethyltryptamine (“5-MeO-DMT”) for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment has been approved by the Argentinian Institutional Review Board.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 27Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant DepressionBiomind Labs Inc. announced that it has commenced dose administration of the first subject in a Phase I/IIa clinical trial of the Company’s novel drug candidate BMND01, for treatment-resistant depression with inhaled administration. The Phase I/IIa clinical trial on Biomind's first innovative formulation of N,N-Dimethyltryptamine (“DMT”) is evaluating the safety, pharmacokinetics, behavioral and brain effects of BMND01, for inhaled administration. The trial has commenced on time and as scheduled and is being administered by superior medical practices at Biomind's new clinical psychedelic research facility in the University Hospital Onofre Lopes. Led by Dr. Dráulio Araújo, Biomind’s Scientific and Clinical advisor, the team is a renowned group of scientists that conducted the first randomized placebo-controlled trial with ayahuasca for treatment-resistant depression.お知らせ • Mar 05Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07Biomind Labs Inc. announced positive results from in vivo studies. Biomind Labs’ BMND07 drug candidate, a novel DMT combination drug, proved to be physiologically safe, showing low acute oral toxicity and no mutagenic effect in all administered dosages in animals.お知らせ • Nov 25Biomind Labs Inc. Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D PrintingBiomind Labs Inc. announced the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various inflammatory disorders.お知らせ • Oct 01Biomind Labs Files International Patent Application on its DMT Candidates Across 153 Global JurisdictionsBiomind Labs Inc. announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. This innovative technology, designed by the scientific team, has the potential to provide new levels of safety for both the patients and also the physicians who will be prescribing these medications. The company view this technology as marking a new concept within the psychedelic industry to increase the quality of treatments while ensuring their traceability. The objective is to provide the confidence that health agencies and government authorities require to start supporting this disruptive way of treating conditions such as depression, anxiety, addictive disorders, eating disorders and chronic pain, among others.Board Change • Sep 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Ravi Sood was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元BMNDCA PharmaceuticalsCA 市場7D0%6.1%-2.2%1Yn/a71.9%29.3%株主還元を見る業界別リターン: BMNDがCanadian Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: BMND Canadian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is BMND's price volatile compared to industry and market?BMND volatilityBMND Average Weekly Movementn/aPharmaceuticals Industry Average Movement11.4%Market Average Movement10.0%10% most volatile stocks in CA Market17.4%10% least volatile stocks in CA Market3.8%安定した株価: BMNDの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のBMNDのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aAlejandro Antalichwww.biomindlabs.comバイオテクノロジーの研究開発会社であるバイオマインド・ラボ社は、様々な精神・神経疾患のための新規医薬品とナノテク送達システムの開発に注力している。BMND01はうつ病治療薬として第II相臨床試験中、BMND08は5-メトキシ-N,N-ジメチルトリプタミンベースの製剤でアルツハイマー型認知障害患者のうつ病と不安症の治療薬として第II相臨床試験中、BMND06は病的肥満症治療薬として第I相臨床試験中、BMDO9はパーキンソン病治療薬として第I相臨床試験中である。また、線維筋痛症治療薬BMND02、嗜癖性障害治療薬BMND03、慢性疼痛治療薬BMND05、炎症性障害治療薬BMND06、大うつ病性障害治療薬BMND07などの新薬候補および前臨床薬の開発も進めている。本社はウルグアイのカネロネス。もっと見るBiomind Labs Inc. 基礎のまとめBiomind Labs の収益と売上を時価総額と比較するとどうか。BMND 基礎統計学時価総額CA$12.97m収益（TTM）-CA$1.24m売上高(TTM)n/a0.0xP/Sレシオ-10.5xPER（株価収益率BMND は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BMND 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$887.75k収益-US$887.75k直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.011グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-43.4%BMND の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 12:03終値2026/06/01 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biomind Labs Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$134k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$134k free cash flow). Shares are highly illiquid. Negative equity (-US$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.31m).
お知らせ • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.
お知らせ • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.
Board Change • Dec 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Scott Ackerman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.
Board Change • Mar 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$134k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$134k free cash flow). Shares are highly illiquid. Negative equity (-US$1.8m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.8m market cap, or US$9.31m).
お知らせ • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.
お知らせ • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.
Board Change • Dec 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Scott Ackerman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.
Board Change • Mar 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jan 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jan 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). CFO & Director Oscar León Bentancor was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • Nov 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (74% average weekly change). Negative equity (-US$1.1m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (CA$33.4m market cap, or US$23.8m).
お知らせ • Jul 19Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical TrialBiomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays.
Board Change • Jun 04No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Dec 07No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Shares are highly illiquid. Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (CA$10.1m market cap, or US$7.48m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end).
Board Change • Nov 24No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Nov 07New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$10.3m (US$7.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Shares are highly illiquid. Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (CA$10.3m market cap, or US$7.48m).
Board Change • Nov 07No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Oct 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 15Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical ApplicationsBiomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges.
Board Change • Aug 25No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Jun 23No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 10No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Ben Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 29Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s DiseaseBiomind Labs Inc. announced that it has successfully completed the development of a novel sublingual formulation to be used in the Phase II trial for its 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”)-based BMND08 candidate for the potential treatment of depression and anxiety in Alzheimer’s disease.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 15Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant DepressionBiomind Labs Inc. announced that the U.S. Food and Drug Administration (“FDA”) has given the Company Investigational New Drug (“IND”) clearance related to the Company’s New Chemical Entity (“NCE”) Triptax™.
お知らせ • Nov 05Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant DepressionBiomind Labs Inc. announced positive initial results from part I of its Phase II trial on its BMND01 candidate, a novel liquid inhaled formulation of N,N-Dimethyltryptamine (DMT) for Treatment-Resistant Depression (TRD). The trial, led by Professor Dráulio Araújo, Ph.D., has involved a dose exploration schedule ranging from 5 to 100 mg. No volunteer presented serious adverse events or clinical risk to the 11 different doses tested. The experimental design of this open-label ascending dose trial involved developing and implementing a proprietary clinical-experimental protocol based on the fundamentals of interventional psychiatry. This multidisciplinary approach combines a psychiatric procedure for dosing DMT associated with psychological support under strict clinical standards.
お知らせ • Oct 12Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant DepressionBiomind Labs Inc. announced a Pre-Investigational New Drug (“Pre-IND”) meeting granted by the U.S. Food and Drug Administration (the “FDA”) for the Company’s new chemical entity (“NCE”) Triptax™. The Company has submitted a briefing package to the Division of Psychiatry, Center for Drug Evaluation and Research at the FDA, and awaits further feedback on the NCE Triptax™. The Pre-IND meeting is a critical step in the U.S. regulatory approval process that provides an opportunity for the Company and the FDA to discuss the NCE development plan and to obtain the FDA’s guidance for new clinical trials the Company may conduct on the NCE Triptax™.
お知らせ • Sep 28Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery SystemBiomind Labs Inc. announced the receipt of a Controlled Substances License and the commencement of an eight-month project to produce and evaluate novel rapidly-dissolving and sustained-release hydrogel-forming microneedle arrays designed for the transdermal delivery of Biomind’s key psychedelic compounds: N, N-dimethyltryptamine (“DMT”), 5-methoxyN,N-dimethyltryptamine (“5-MeO-DMT”) and mescaline. The use of polymeric microneedle array patches (“MAPs”) is an attractive way of delivering drugs through the skin. Upon MAP application, microneedles painlessly penetrate the outer layer of the skin, creating temporary microchannels in this highly effective barrier to diffusion, through which enhanced transdermal drug delivery can be achieved. Given the presence of a dense network of blood vessels in the deeper layers of the skin, drugs can be absorbed into the plasmatic circulation and distributed to the entire body, producing a systemic effect. Additional advantages of this technology, such as the avoidance of first-pass metabolism and drug delivery in a rate-controlled or long-acting manner, can serve to reduce the incidence of side-effects and dosing frequency, which in turn may lead to increased treatment adherence.
お知らせ • Sep 22Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant DepressionBiomind Labs Inc. announced the completion of dose administration of 30 healthy subjects in the Company’s Phase II trial of its novel drug candidate BMND01 for Treatment-Resistant Depression. 10% to 30% of people with depression exhibit treatment-resistant symptoms coupled with difficulties in social and occupational function, decline of physical health, poor quality of life, suicide ideation and attempts, self-injurious behavior, high relapse rate and increased health care utilization. The objectives of the trial are to establish the safety and tolerability of DMT. In addition to evaluating side effects, thistrial will also allow Biomind to explore the origin of the observed side effects, given that different associated physiological, behavioral, and cognitive markers will be collected before, during, and after the trial.
Board Change • Jul 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 08Biomind Labs Inc., Annual General Meeting, Jun 28, 2022Biomind Labs Inc., Annual General Meeting, Jun 28, 2022, at 10:00 US Eastern Standard Time. Agenda: To receive the audited financial statements of the Corporation for the financial year ended December 31, 2021, together with the report of the auditor thereon; to appoint MNP LLP, Chartered Professional Accountants, as auditor of the Corporation for the ensuing year and to authorize the directors of the Corporation to fix the remuneration of the auditor; to elect the directors of the Corporation for the ensuing year; and to transact such other business as may properly be brought before the Meeting or any adjournment or adjournments thereof.
お知らせ • May 27Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s DiseaseBiomind Labs Inc. announced that a third Phase II clinical trial for its BMND08 candidate based on 5-Methoxy-N,N-dimethyltryptamine (“5-MeO-DMT”) for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment has been approved by the Argentinian Institutional Review Board.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 27Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant DepressionBiomind Labs Inc. announced that it has commenced dose administration of the first subject in a Phase I/IIa clinical trial of the Company’s novel drug candidate BMND01, for treatment-resistant depression with inhaled administration. The Phase I/IIa clinical trial on Biomind's first innovative formulation of N,N-Dimethyltryptamine (“DMT”) is evaluating the safety, pharmacokinetics, behavioral and brain effects of BMND01, for inhaled administration. The trial has commenced on time and as scheduled and is being administered by superior medical practices at Biomind's new clinical psychedelic research facility in the University Hospital Onofre Lopes. Led by Dr. Dráulio Araújo, Biomind’s Scientific and Clinical advisor, the team is a renowned group of scientists that conducted the first randomized placebo-controlled trial with ayahuasca for treatment-resistant depression.
お知らせ • Mar 05Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07Biomind Labs Inc. announced positive results from in vivo studies. Biomind Labs’ BMND07 drug candidate, a novel DMT combination drug, proved to be physiologically safe, showing low acute oral toxicity and no mutagenic effect in all administered dosages in animals.
お知らせ • Nov 25Biomind Labs Inc. Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D PrintingBiomind Labs Inc. announced the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering. The form contains as its active ingredients certain psychedelic molecules that the Company has in its portfolio of psychedelic candidates. This pharmaceutical form is aimed at alleviating neurological and psychiatric disorders, and acting as an anti-inflammatory agent for various inflammatory disorders.
お知らせ • Oct 01Biomind Labs Files International Patent Application on its DMT Candidates Across 153 Global JurisdictionsBiomind Labs Inc. announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. This innovative technology, designed by the scientific team, has the potential to provide new levels of safety for both the patients and also the physicians who will be prescribing these medications. The company view this technology as marking a new concept within the psychedelic industry to increase the quality of treatments while ensuring their traceability. The objective is to provide the confidence that health agencies and government authorities require to start supporting this disruptive way of treating conditions such as depression, anxiety, addictive disorders, eating disorders and chronic pain, among others.
Board Change • Sep 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Ravi Sood was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
